SLC5A2 and hydrops fetalis: The European Society of Cardiology’s recently released HF treatment guidelines emphasize four “key disease-modifying drugs”, mainly including beta-blockers, renin-angiotensin-aldosterone system inhibitors, and mineralocorticoid receptor antagonists and sodium-glucose cotransporter 2 inhibitors (46).